FDA Approves Shock Absorber You Can Actually Implant in Your Knee
Published Date: 6/29/2026
Rule
Summary
The FDA is officially classifying the medial knee implanted shock absorber as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative knee device faster and with confidence in its safety. The new classification is effective June 29, 2026, and could save time and money for makers and users alike.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 0 costs, 1 mixed.
Medial Knee Shock Absorber Now Class II
The FDA classified the medial knee implanted shock absorber as a Class II device with special controls, effective June 29, 2026 (classification applicable April 10, 2023). FDA says this reduces regulatory burdens and is intended to enhance patient access and speed availability of this knee implant.
Manufacturers Must Use 510(k) Pathway
The medial knee implanted shock absorber is subject to premarket notification under section 510(k), meaning device sponsors must submit a 510(k) to market this Class II device unless FDA later exempts it. FDA also notes a De Novo-classified device can serve as a predicate for future 510(k) submissions.
Required Testing, Training, and Labeling Controls
FDA codified special controls for the device that require: clinical data showing improved knee function and relevant adverse events; non-clinical performance testing (mechanical function, durability, fretting/corrosion, static strength, wear, fatigue, worst-case range of motion); biocompatibility; sterility and pyrogenicity data; reprocessing validation for reusable components; shelf-life demonstration; a training program for safe implantation; and labeling that includes validated reprocessing instructions and a shelf life.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13006 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The FDA has officially set the review period for the drug VYALEV, which helps the company extend its patent protection. This means the patent clock can be paused, giving the drug maker more time to sell VYALEV exclusively. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by late 2026.
2026-13005 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Species
The FDA is asking for public feedback on their plan to keep collecting info about new animal drugs for rare uses and less common species. This affects drug makers who want special approval and incentives for these unique animal medicines. Comments are open until July 29, 2026, and the process helps keep these important drugs safe and available without extra costs.
2026-12884 — Agency Information Collection Activities; Proposed Collection; Comment Request; Time and Extent Applications for Nonprescription Drug Products
The FDA wants your thoughts on how they collect info about nonprescription drug applications, especially about timing and usage. This affects drug makers and anyone interested in over-the-counter meds. You’ve got until August 25, 2026, to share your comments—no fees, just your voice helping shape the process!
2026-12906 — Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability
The FDA has officially ended emergency use for three COVID-19 test kits from BD, InBios, and Roche as of early 2026. This means these specific tests are no longer authorized for quick COVID-19 detection or diagnosis. If you or your organization used these tests, it’s time to switch to other approved options—no extra costs or penalties, just a smooth transition.
2026-12937 — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period
The FDA is giving folks more time to share their thoughts on whether certain medicines like semaglutide, tirzepatide, and liraglutide should be allowed for special compounding by outsourcing drug makers. This extension means anyone interested has until July 30, 2026, to weigh in. It affects drug makers, healthcare pros, and patients waiting for these meds, with no immediate cost changes but plenty of chances to influence future drug availability.
Previous / Next Documents
Previous: 2026-13092 — Technical Guidelines for the Production of Regenerative Agricultural Biofuel Feedstocks
Starting July 29, 2026, farmers growing crops for biofuels will follow new, clearer rules to measure and report how their farming practices reduce carbon emissions. These updated guidelines help track the environmental impact from farm to fuel, making it easier to prove greener biofuel production. This affects farmers, biofuel producers, and supply chain folks, aiming to boost cleaner energy while keeping reporting fair and accurate.
Next: C1-2026-10036 — Real Estate Lending Escrow Accounts
Starting soon, banks and lenders must follow new rules about real estate escrow accounts, which hold money for things like taxes and insurance. These changes mainly affect lenders and borrowers by making escrow handling clearer and more consistent. The updated rules kick in right away, aiming to protect your money and keep things fair.